The immune system, amyloid-β peptide, and Alzheimer's disease

Immunological Reviews

Volumn 205, Issue , 2005, Pages 244-256

  Weksler, Marc E ^a   Gouras, Gunnar ^a   Relkin, Norman R ^a   Szabo, Paul ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M266; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; CELLULAR IMMUNITY; COGNITION; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BRAIN; HUMANS; IMMUNOTHERAPY;

EID: 20344384992     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00264.x     Document Type: Review

References (78)

1. Thucydides. The Peloponnesian War. New York: Modern Library, 1934:112.
2. Leung AKC. "Variolation" and vaccination in late imperial China, ca 1570-1911. In: Plotkin SA, Fantini B, eds. Vaccinia, Vaccination, Vaccinology. Paris: Elsevier, 1996:65.
3. Baxby D. Edward Jenner's role in the introduction of smallpox vaccine p59. In: Plotkin SA, Fantini B, eds. Vaccinia, Vaccination, Vaccinology. Paris: Elsevier, 1996.
4. Jenner E. An Inquiry Into the Causes and Effects of the Variolae Vaccine, a Disease Discovered in Some of the Western Counties of England Particularly Gloucestershire, and Known by the Name of the Cow Pox. London: Sampson Low, 1798.
5. von Behring EA, Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Theiren. Deutsche Med Wochenschr 1890;16:1113-1114.
6. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
7. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet 1968;2:24-26.
8. Bovbjerg DH, Kim YT, Schwab R, Schmitt K, DeBlasio T, Weksler ME. "Cross-wiring" of the immune response in old mice: increased autoantibody response despite reduced antibody response to nominal antigen. Cell Immunol 1991;135:519-525.
9. Walford RL. The Immunologic Theory of Aging. Philadelphia: Williams & Wilkins, 1969.
10. Grabar P. Autoantibodies and the physiological role of immunoglobulins. Immunol Today 1983;4:337-340.
11. Weksler ME, Goodhardt M, Szabo P. The effect of age on B cell development and humoral immunity. Springer Semin Immunopathol 2002;24:35-52.
12. Areaza EE, Gibbons JJ, Siskind GW, Weksler ME. Lower antibody response to tetanus toxoid associated with higher auto-antiidiotypic antibody in old compared with young humans. Clin Exp Immunol 1993;92:169-173.
13. Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 2004;16:616-622.
14. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998;102:910-918.
15. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002;37:943-948.
16. Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
17. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1994;122:1131-1135.
18. Kang J, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
19. Hardy J. Toward Alzheimer therapies based on genetic knowledge. Annu Rev Med 2004;55:15-25.
20. Games D, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-527.
21. Hsia AY, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999;96:3228-3233.
22. McLean CA, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
23. Naslund J, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc 2000;283:1571-1577.
24. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:14657-14662.
25. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci 2001;17:37-45.
26. Gouras GK, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000;156:15-20.
27. Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003;39:409-421.
28. Chen G, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000;408:975-979.
29. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
30. Canevari L, Abramov AY, Duchen MR. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem Res 2004;29:637-650.
31. Kuo YM, et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999;257:787-791.
32. Li Q, et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 2004;5:21-28.
33. Sigurdsson EM, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004;24:6277-6282.
34. Postina R, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004;113:1456-1464.
35. Iwatsubo T. Abeta42, presenilins, and Alzheimer's disease. Neurobiol Aging 1998;19:S11-S13.
36. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-4112.
37. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 1998;4:827-831.
38. Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-6453.
39. Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
40. Liu L, Tapiola T, Herukka SK, Heikkila M, Tanila H. Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport 2003;14:163-166.
41. Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003;23:8844-8853.
42. Nitsch RM, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-518.
43. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K. Age-dependent change in the level of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000;43:155-160.
44. Pirttila T, et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Arch Neurol 1996;53:189-193.
45. Mayeux R, et al. Plasma A (beta) 40 and A (beta) 42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-1190.
46. Kuo YM, et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000;268:750-756.
47. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-2267.
48. Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein - Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 1997;94:213-222.
49. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:10273-10278.
50. Monning U, et al. Alzheimer amyloid βA4 protein reactive antibodies in human sera and CSF. In: Iqbal K, et al., eds. Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. Chichester, NY: Wiley, 1991.
51. Du Y, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001;57:801-805.
52. Hyman BT, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 2001;49:808-810.
53. Mruthinti S, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004;25:1023-1032.
54. Brettschneider S, et al. Decreased serum amyloid-B1 - 42 autoantibody levels in alzheimer's disease using a newly developed immuno-precipitation assay with radiolabelled amyloid B1-42 peptide (in press).
55. Moir RD, et al. Levels of autoantibodies to redox-modified Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005; in press.
56. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol Aging 1996;17:541-547.
57. Monsonego A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112:415-422.
58. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16-32.
59. Cherny RA, et al. Treatment with a copper - zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
60. Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
61. Janus C, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
62. Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
63. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-828.
64. Pfeifer M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379.
65. Dodart JC, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457.
66. Kotilinek LA, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-6335.
67. Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.
68. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-452.
69. Hock C, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002;8:1270-1275.
70. Hock C, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554.
71. Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
72. -/- knock-out mice. J Neurosci 2003;23:8532-8538.
73. Bacskai BJ, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22:7873-7878.
74. Bard F, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-2028.
75. Du Y, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003;126:1935-1939.
76. Dodel RC, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-1474.
77. Relkin NR, Szabo P, Du Monthé CY, Schiff R, Weksler ME. Alzheimers disease (AD) patients treated with intravenous immunoglobulin (IVIg) increase their plasma anti-β-amyloid antibody titers and β-amyloid levels in a dose-dependent fashion. Abstract, American Academy of Neurology, 2005.
78. Schiff RI. Intravenous immunoglobulins for treatment of antibody deficiencies. In: Good RA, Lindenlaub E, eds. The Nature, Cellular and Biochemical Basis and Management of Immunodeficiencies. Stuttgart: F.K. Schattauer Verlag, 1987:523-541.